| Basics |
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.
|
| IPO Date: |
September 7, 2005 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.96B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.36 | 2.14%
|
| Avg Daily Range (30 D): |
$1.65 | 1.56%
|
| Avg Daily Range (90 D): |
$2.10 | 1.93%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.31M |
| Avg Daily Volume (30 D): |
.07M |
| Avg Daily Volume (90 D): |
.07M |
| Trade Size |
| Avg Trade Size (Sh.): |
107 |
| Avg Trade Size (Sh.) (30 D): |
28 |
| Avg Trade Size (Sh.) (90 D): |
30 |
| Institutional Trades |
| Total Inst.Trades: |
5,258 |
| Avg Inst. Trade: |
$3.1M |
| Avg Inst. Trade (30 D): |
$1.95M |
| Avg Inst. Trade (90 D): |
$2.12M |
| Avg Inst. Trade Volume: |
.03M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.18M |
| Avg Closing Trade (30 D): |
$1.98M |
| Avg Closing Trade (90 D): |
$2.13M |
| Avg Closing Volume: |
30.07K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-7.2
|
$-2.21
|
$-1.72
|
|
Diluted EPS
|
$-7.16
|
$-2.21
|
$-1.68
|
|
Revenue
|
$ 181.49M
|
$ 45.33M
|
$ 42.81M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -132.62M
|
$ -42.45M
|
$ -31.09M
|
|
Operating Income / Loss
|
$ -61.81M
|
$ -36.22M
|
$ -9.64M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -2.03M
|
$ -24.24M
|
$ 8.69M
|
|
PE Ratio
|
|
|
|
|
